Tocilizumab biosimilar - Enzene Biosciences
Alternative Names: Tocilizumab - EnzeneLatest Information Update: 28 Jan 2026
At a glance
- Originator Enzene Biosciences
- Class Anti-inflammatories; Antineoplastics; Antirheumatics; Antivirals; Immunotherapies; Monoclonal antibodies; Skin disorder therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Interleukin 6 receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 28 Jan 2026 No recent reports of development identified for research development in Rheumatoid-arthritis in India (SC)
- 24 Dec 2021 Theramex enters into a development and commercialization agreement with Enzene Biosciences for tocilizumab biosimilar in Rheumatoid arthritis
- 24 Dec 2021 Early research in Rheumatoid arthritis in India (SC)